Silver (Ag; massive, powder and nanoform) and Ag compounds are used in industrial, medical and consumer applications, with potential for human exposure. Uncertainties exist about their comparative mammalian toxicokinetic (‘TK’) profiles, including their relative oral route bioavailability, especially for Ag massive and powder forms. This knowledge gap impedes concluding on the grouping of Ag and Ag compounds for hazard assessment purposes. Therefore, an in vivo TK study was performed in a rat model. Sprague–Dawley rats were exposed via oral gavage for up to 28 days to silver acetate (AgAc; 5, 55, 175 mg/kg(bw)/d), silver nitrate (AgNO3; 5, 55, 125 mg/kg(bw)/d), nanosilver (AgNP; 15 nm diameter; 3.6, 36, 360 mg/kg(bw)/d) or silver powder (AgMP; 0.35 µm diameter; 36, 180, 1000 mg/kg(bw)/d). Total Ag concentrations were determined in blood and tissues to provide data on comparative systemic exposure to Ag and differentials in achieved tissue Ag levels. AgAc and AgNO3were the most bioavailable forms with comparable and linear TK profiles (achieved systemic exposures and tissue concentrations). AgMP administration led to systemic exposures of about an order of magnitude less, with tissue Ag concentrations 2–3 orders of magnitude lower and demonstrating non-linear kinetics. The apparent oral bioavailability of AgNP was intermediate between AgAc/AgNO3and AgMP. For all test items, highest tissue Ag concentrations were in the gastrointestinal tract and reticuloendothelial organs, whereas brain and testis were minor sites of distribution. It was concluded that the oral bioavailability of AgMP was very limited. These findings provide hazard assessment context for various Ag test items and support the prediction that Ag in massive and powder forms exhibit low toxicity potential.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00204-023-03511-6.